Altacor currently markets products in the Dry Eye and other (Blepharitis) segments. In addition, Altacor has nutritional supplement in the retinal segment for the prevention of progression of dry age-related macular degeneration (AMD). R&D pipeline programmes covering surgery and glaucoma are in progress.
Altacor intends to enhance its ophthalmology portfolio via in-licensing or acquiring rights to marketed or late-stage product opportunities for European sale that target important and fast-growing areas of medical need. Altacor is particularly interested in products for orphan indications, glaucoma/cataract surgery and back-of-the-eye diseases (dry and wet AMD).
Altacor’s product pipeline is supported variously by patents, orphan designations, licences, know-how and trademarks.
The Altacor Approach
The Company’s approach to the development of its product portfolio is primarily by reformulation and reprofiling of existing compounds with established clinical activity and systemic safety. Reprofiling has proved to be successful for many currently marketed ophthalmology products.